European Vaccine Markets: Germany, UK, France, Spain, Italy, Rest of EuropeKalorama InformationNovember 1, 2010 150 Pages - SKU: KLI2833006 |
Additional Information
In 2009, the adult flu vaccine market in Europe reached new heights with nearly $1.6 billion in revenues, up 81.4% from the prior year. According to healthcare market research publisher Kalorama Information's newly published European Vaccine Markets, this surge in flu vaccine sales was due to products developed to address the H1N1 flu pandemic.
Influenza vaccines are responsible for almost half of the adult vaccine market in 2010. Although Kalorama does not foresee the same kind of growth witnessed in 2009, the publisher expects strong demand for flu vaccines to continue, supported by an aging population and expanded recommendations for adult influenza vaccinations, though tempered by a near term decrease in demand for pandemic vaccines.
"The swine flu pandemic of 2009 prompted a flurry of activity in the flu vaccines market around the world, with a resulting surge in revenues," says Bruce Carlson, publisher of Kalorama Information. "This growth is unlikely to continue as governments overestimated the demand for H1N1 flu vaccines and found themselves with excess stock. Current development initiatives focus on products that protect against pandemic outbreaks, specific strains of influenza and alternative administration routes."
In May 2008, GlaxoSmithKline received European approval for Prepandrix and Pandemrix; each contains the H5N1 (avian flu) inactivated split, monovalent virus. Prepandrix is designed to be given before or at the onset of a declared influenza pandemic to prevent influenza caused by H5N1. It is formulated with a novel proprietary adjuvant system, which is designed to achieve a high immune response at a low dose of antigen, and to be long-lasting and active against a broad range of H5N1 strains. Pandemrix is approved for use when an H5N1 influenza pandemic has been officially declared by the WHO or European Union. In December 2008, the European Medicines Agency (EMEA) issued a positive opinion for Baxter's CELVAPAN, the first cell culture-based H5N1 pandemic vaccine, in the European Union. CELVAPAN is made using Baxter's proprietary Vero cell technology, which speeds up the manufacturing process due to its ability to use the native virus which does not need to be modified in order to grow in chicken eggs. The shorter production time is critical in accelerating vaccine supply in response to an influenza pandemic. Also of note are advancing efforts to develop a universal flu vaccine which would protect against multiple influenza strains, thereby significantly increasing effectiveness. While many companies over the years have investigated methods to achieve this, U.K.-based Immune Targeting Systems, with funding from a broad range of investors including Novartis's venture capital group, is expected to begin studies of a product candidate in 2010. More information on flu and other types of vaccines in the European market can be found in Kalorama Information's European Vaccine Markets. This report presents market estimates and forecasts, product reviews and pipelines, issues and trends, and company profiles for pediatric and adult vaccines.More Pandemic Vaccines reports by Kalorama Information
Vaccines 2012-16 World Market Analysis, Key Players, Trends, Pediatric and Adult Segments by Kalorama Information
This report examines the market for vaccines used in humans to previous various types of disease. It covers only commercialized vaccines and developmental vaccines for ...
What's Next In Vaccines (Malaria, Diabetes, Alzheimer's, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline) by Kalorama Information
Vaccines are one of the most dynamic parts of the pharmaceutical business today but future growth will depend on a considerable amount of potential vaccines ...
Vaccine Production (Trends, Techniques, Key Players, Spending Estimates and Forecasts) by Kalorama Information
Vaccines are among the top revenue earners in recent years, and in some cases have assisted major pharmaceutical companies to revenue growth. But this ...
Asian Vaccine Markets: India, China, Japan, Korea, Indonesia and Rest of Asia by Kalorama Information
See all reports like this >>The Asian vaccine market is relatively small compared to its population, yet it is growing, and pharmaceutical manufacturers increasingly will look to boost sales from ...
More Europe Pandemic Vaccines reports
PharmaPoint: Seasonal Influenza Vaccines United Kingdom Drug Forecast and Market Analysis by GlobalData
PharmaPoint: Seasonal Influenza Vaccines United Kingdom Drug Forecast and Market AnalysisSummaryGlobalData has released its new Country report, “PharmaPoint: Seasonal Influenza Vaccines United Kingdom Drug Forecast ...
PharmaPoint: Seasonal Influenza Vaccines Spain Drug Forecast and Market Analysis by GlobalData
PharmaPoint: Seasonal Influenza Vaccines Spain Drug Forecast and Market AnalysisSummaryGlobalData has released its new Country report, “PharmaPoint: Seasonal Influenza Vaccines Spain Drug Forecast and Market ...
PharmaPoint: Seasonal Influenza Vaccines Italy Drug Forecast and Market Analysis by GlobalData
PharmaPoint: Seasonal Influenza Vaccines Italy Drug Forecast and Market AnalysisSummaryGlobalData has released its new Country report, “PharmaPoint: Seasonal Influenza Vaccines Italy Drug Forecast and Market ...
PharmaPoint: Seasonal Influenza Vaccines France Drug Forecast and Market Analysis by GlobalData
See all reports like this >>PharmaPoint: Seasonal Influenza Vaccines France Drug Forecast and Market AnalysisSummaryGlobalData has released its new Country report, “PharmaPoint: Seasonal Influenza Vaccines France Drug Forecast and Market ...
More Europe reports
Painters & Decorators - Scotland (UK) - Industry Report by Plimsoll Publishing Ltd.
Plimsoll Publishing’s UK Painters & Decorators - Scotland Analysis provides a detailed overview of the UK Painters & Decorators - Scotland market and delivers a ...
Tampons Market in Czech Republic to 2016 by Canadean Ltd
SynopsisThe report presents detailed data on consumption trends in the Tampons category in Czech Republic, analyzing consumption volumes and values. It also provides indispensable data ...
D&B Country Report: Portugal by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
D&B Country Report: Sweden by Dun & Bradstreet Inc.
See all reports like this >>D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
Pandemic Vaccines Reports
- Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants
- Forecast: Pneumococcal Vaccines
- PharmaPoint: Seasonal Influenza Vaccines - Current and Future Players
- EpiCast Report: Seasonal Influenza Vaccines Epidemiology Forecast to 2022
- Influenza VLP Vaccine (Seasonal Influenza Vaccines) Forecast and Market Analysis